Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Trials ; 25(1): 366, 2024 Jun 07.
Article in English | MEDLINE | ID: mdl-38849943

ABSTRACT

BACKGROUND: Chemotherapy with lomustine is widely considered as standard treatment option for progressive glioblastoma. The value of adding radiotherapy to second-line chemotherapy is not known. METHODS: EORTC-2227-BTG (LEGATO, NCT05904119) is an investigator-initiated, pragmatic (PRECIS-2 score: 34 out of 45), randomized, multicenter phase III trial in patients with first progression of glioblastoma. A total of 411 patients will be randomized in a 1:1 ratio to lomustine (110 mg/m2 every 6 weeks) or lomustine (110 mg/m2 every 6weeks) plus radiotherapy (35 Gy in 10 fractions). Main eligibility criteria include histologic confirmation of glioblastoma, isocitrate dehydrogenase gene (IDH) wild-type per WHO 2021 classification, first progression at least 6 months after the end of prior radiotherapy, radiologically measurable disease according to RANO criteria with a maximum tumor diameter of 5 cm, and WHO performance status of 0-2. The primary efficacy endpoint is overall survival (OS) and secondary endpoints include progression-free survival, response rate, neurocognitive function, health-related quality of life, and health economic parameters. LEGATO is funded by the European Union's Horizon Europe Research program, was activated in March 2024 and will enroll patients in 43 sites in 11 countries across Europe with study completion projected in 2028. DISCUSSION: EORTC-2227-BTG (LEGATO) is a publicly funded pragmatic phase III trial designed to clarify the efficacy of adding reirradiation to chemotherapy with lomustine for the treatment of patients with first progression of glioblastoma. TRIAL REGISTRATION: ClinicalTrials.gov NCT05904119. Registered before start of inclusion, 23 May 2023.


Subject(s)
Antineoplastic Agents, Alkylating , Brain Neoplasms , Disease Progression , Glioblastoma , Lomustine , Multicenter Studies as Topic , Progression-Free Survival , Glioblastoma/pathology , Glioblastoma/drug therapy , Glioblastoma/mortality , Glioblastoma/radiotherapy , Glioblastoma/therapy , Humans , Lomustine/administration & dosage , Lomustine/therapeutic use , Lomustine/adverse effects , Brain Neoplasms/radiotherapy , Brain Neoplasms/pathology , Brain Neoplasms/mortality , Brain Neoplasms/therapy , Antineoplastic Agents, Alkylating/therapeutic use , Quality of Life , Randomized Controlled Trials as Topic , Chemoradiotherapy/methods , Clinical Trials, Phase III as Topic , Pragmatic Clinical Trials as Topic , Time Factors
2.
Radiother Oncol ; 186: 109775, 2023 09.
Article in English | MEDLINE | ID: mdl-37385376

ABSTRACT

PURPOSE: To demonstrate the feasibility of characterising MLCs and MLC models implemented in TPSs using a common set of dynamic beams. MATERIALS AND METHODS: A set of tests containing synchronous (SG) and asynchronous sweeping gaps (aSG) was distributed among twenty-five participating centres. Doses were measured with a Farmer-type ion chamber and computed in TPSs, which provided a dosimetric characterisation of the leaf tip, tongue-and-groove, and MLC transmission of each MLC, as well as an assessment of the MLC model in each TPS. Five MLC types and four TPSs were evaluated, covering the most frequent combinations used in radiotherapy departments. RESULTS: Measured differences within each MLC type were minimal, while large differences were found between MLC models implemented in clinical TPSs. This resulted in some concerning discrepancies, especially for the HD120 and Agility MLCs, for which differences between measured and calculated doses for some MLC-TPS combinations exceeded 10%. These large differences were particularly evident for small gap sizes (5 and 10 mm), as well as for larger gaps in the presence of tongue-and-groove effects. A much better agreement was found for the Millennium120 and Halcyon MLCs, differences being within ± 5% and ± 2.5%, respectively. CONCLUSIONS: The feasibility of using a common set of tests to assess MLC models in TPSs was demonstrated. Measurements within MLC types were very similar, but TPS dose calculations showed large variations. Standardisation of the MLC configuration in TPSs is necessary. The proposed procedure can be readily applied in radiotherapy departments and can be a valuable tool in IMRT and credentialing audits.


Subject(s)
Radiotherapy Planning, Computer-Assisted , Radiotherapy, Intensity-Modulated , Humans , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods , Phantoms, Imaging , Radiometry/methods , Radiotherapy, Intensity-Modulated/methods
3.
Neurol India ; 71(Supplement): S146-S152, 2023.
Article in English | MEDLINE | ID: mdl-37026346

ABSTRACT

Background: Brain metastases are the most common brain tumors, being one of the most frequent neurological complications of systemic cancer and an important cause of morbidity and mortality. Stereotactic radiosurgery is efficacious and safe in the treatment of brain metastases, with good local control rates and low adverse effects rate. Large brain metastases present some issues in balancing local control and treatment-related toxicity. Objective: Demonstrating adaptive staged-dose Gamma Knife radiosurgery (ASD-GKRS) being a safe and effective treatment for large brain metastases. Materials and Methods: We retrospectively analyzed our series of patients treated with two-stage Gamma Knife radiosurgery for large brain metastases in [BLINDED], between February 2018 and May 2020. Results: Forty patients with large brain metastases underwent adaptive staged-dose Gamma Knife radiosurgery, with median prescription dose of 12 Gy and a median interval between stages of 30 days. At three-month follow-up, the survival rate was 75.0% with a local control rate of 100%. At six-month follow-up, the survival rate was 75.0% with a local control rate of 96.7%. The mean volume reduction was 21.81 cm3 (16.76-26.86; 95% CI). The difference between baseline volume and six-month follow-up volume was statistically significant. Conclusions: Adaptive staged-dose Gamma Knife radiosurgery is a safe, non-invasive and effective treatment for brain metastases, with a low rate of side effects. Large prospective trials are needed to strengthen data obtained about the effectiveness and safety of this technique in managing large brain metastases.


Subject(s)
Brain Neoplasms , Radiosurgery , Humans , Radiosurgery/methods , Retrospective Studies , Prospective Studies , Treatment Outcome , Brain Neoplasms/radiotherapy , Brain Neoplasms/surgery , Brain Neoplasms/etiology , Follow-Up Studies
4.
Radiother Oncol ; 159: 106-111, 2021 06.
Article in English | MEDLINE | ID: mdl-33741471

ABSTRACT

PURPOSE: To promote consistency in clinical trials by recommending a uniform framework as it relates to radiation transport and dose calculation in water versus in medium. METHODS: The Global Quality Assurance of Radiation Therapy Clinical Trials Harmonisation Group (GHG; www.rtqaharmonization.org) compared the differences between dose to water in water (Dw,w), dose to water in medium (Dw,m), and dose to medium in medium (Dm,m). This was done based on a review of historical frameworks, existing literature and standards, clinical issues in the context of clinical trials, and the trajectory of radiation dose calculations. Based on these factors, recommendations were developed. RESULTS: No framework was found to be ideal or perfect given the history, complexity, and current status of radiation therapy. Nevertheless, based on the evidence available, the GHG established a recommendation preferring dose to medium in medium (Dm,m). CONCLUSIONS: Dose to medium in medium (Dm,m) is the preferred dose calculation and reporting framework. If an institution's planning system can only calculate dose to water in water (Dw,w), this is acceptable.


Subject(s)
Radiotherapy Planning, Computer-Assisted , Water , Consensus , Humans , Monte Carlo Method , Radiotherapy Dosage
5.
Tumori ; 107(6): NP41-NP44, 2021 Dec.
Article in English | MEDLINE | ID: mdl-33629653

ABSTRACT

OBJECTIVE: To outline a practical method of performing prostate cancer radiotherapy in patients with bilateral metal hip prostheses with the standard resources available in a modern general hospital. The proposed workflow is based exclusively on magnetic resonance imaging (MRI) to avoid computed tomography (CT) artifacts. CASE DESCRIPTION: This study concerns a 73-year-old man with bilateral hip prostheses with an elevated risk prostate cancer. Magnetic resonance images with assigned electron densities were used for planning purposes, generating a synthetic CT (sCT). Imaging acquisition was performed with an optimized Dixon sequence on a 1.5T MRI scanner. The images were contoured by autosegmentation software, based on an MRI database of 20 patients. The sCT was generated assigning averaged electron densities to each contour. Two volumetric modulated arc therapy plans, a complete arc and a partial one, where the beam entrances through the prostheses were avoided for about 50° on both sides, were compared. The feasibility of matching daily cone beam CT (CBCT) with MRI reference images was also tested by visual evaluations of different radiation oncologists. CONCLUSIONS: The use of magnetic resonance images improved accuracy in targets and organs at risk (OARs) contouring. The complete arc plan was chosen because of 10% lower mean and maximum doses to prostheses with the same planning target volume coverage and OAR sparing. The image quality of the match between performed CBCTs and MRI was considered acceptable. The proposed method seems promising to improve radiotherapy treatments for this complex category of patients.


Subject(s)
Heavy Ion Radiotherapy/standards , Hip Prosthesis/statistics & numerical data , Magnetic Resonance Imaging/methods , Metal-on-Metal Joint Prostheses/statistics & numerical data , Prostatic Neoplasms/pathology , Radiotherapy Planning, Computer-Assisted/standards , Radiotherapy, Image-Guided/methods , Aged , Artifacts , Humans , Image Processing, Computer-Assisted/methods , Male , Organs at Risk , Prostatic Neoplasms/radiotherapy
6.
Radiother Oncol ; 155: 226-231, 2021 02.
Article in English | MEDLINE | ID: mdl-33217496

ABSTRACT

PURPOSE: The EORTC Radiation Oncology Group uses a Facility Questionnaire (FQ) to collect information from its member radiation oncology departments. We analysed the FQ database for patient-related workload, staffing levels and infrastructure to determine developments in radiation oncology departments in the clinical trials community. MATERIALS & METHODS: We exported the FQ database in August 2019. Departments were included if their FQ was created or updated within the two preceding years. Observations were compared with previous evaluations of the FQ database. RESULTS: In total, 161 departments from 24 mostly European countries were analysed. The average number of patients per department increased by 3.0% to 2,453 (2013: 2,381). The annual number of patients decreased by 7.4% to 225 per radiation oncologist (2013: 243) and by 7.9% to 326 per medical physicist (2013: 354). In contrast, the number of patients increased by 23.3% to 106 per radiation therapist (RTT) (2013: 86) and per treatment unit by 3.9 % to 485 (2013: 467). In a pairwise comparison of departments that were available in 2013 and 2019, the number of patients per radiation oncologist (p = 0.02) and per physicist (p = 0.0003) decreased significantly. The number of departments that own a dedicated PET-CT scanner more than doubled (2013: 4%; 2019: 9%) and the availability of stereotactic body radiation therapy (SBRT) increased by 31.8% to 85.7% of the departments (2013: 65%). CONCLUSION: The case-related workload per radiation oncologist and per physicist continues to decrease but increases per RTT and treatment unit. This is likely driven by an increased use of complex techniques, multimodality imaging and the implementation of automation in radiation oncology departments.


Subject(s)
Neoplasms , Workload , Europe , Humans , Neoplasms/radiotherapy , Positron Emission Tomography Computed Tomography , Workforce
7.
Stereotact Funct Neurosurg ; 98(5): 319-323, 2020.
Article in English | MEDLINE | ID: mdl-32726792

ABSTRACT

INTRODUCTION: The WHO declared 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a public health emergency of international concern. The National and Regional Health System has been reorganized, and many oncological patients died during this period or had to interrupt their therapies. This study summarizes a single-centre experience, during the COVID-19 period in Italy, in the treatment of brain metastases with Gamma Knife stereotactic radiosurgery (GKRS). METHODS: We retrospectively analysed our series of patients with brain metastases who underwent GKRS at the Niguarda Hospital from February 24 to April 24, 2020. RESULTS: We treated 30 patients with 66 brain metastases. A total of 22 patients came from home and 8 patients were admitted to the emergency room for urgent neurological symptoms. Duration of stay was limited to 0-1 day in 17 patients. We chose to treat a cluster of 9 patients, whose greater lesion exceeded 10 cm3, with 2-stage modality GKRS to minimize tumour recurrence and radiation necrosis. CONCLUSION: Due to the COVID-19 pandemic, the whole world is at a critical crossroads about the use of health care resources. During the COVID-19 outbreak, the deferral of diagnostic and therapeutic procedures and a work backlog in every medical specialty are the natural consequences of reservation of resources for COVID-19 patients. GKRS improved symptoms and reduced the need for open surgeries, allowing many patients to continue their therapeutic path and sparing beds in ICUs. Neurosurgeons have to take into account the availability of stereotactic radiosurgery to reduce hospital stay, conciliating safety for patients and operators with the request for health care coming from the oncological patients and their families.


Subject(s)
Brain Neoplasms/radiotherapy , Coronavirus Infections , Pandemics , Pneumonia, Viral , Radiosurgery/methods , Aged , Betacoronavirus , Brain Neoplasms/secondary , COVID-19 , Female , Humans , Italy , Male , Middle Aged , Neoplasm Recurrence, Local/surgery , Retrospective Studies , SARS-CoV-2 , Treatment Outcome
8.
Radiother Oncol ; 150: 30-39, 2020 09.
Article in English | MEDLINE | ID: mdl-32504762

ABSTRACT

BACKGROUND AND PURPOSE: The Global Quality Assurance of Radiation Therapy Clinical Trials Harmonization Group (GHG) is a collaborative group of Radiation Therapy Quality Assurance (RTQA) Groups harmonizing and improving RTQA for multi-institutional clinical trials. The objective of the GHG OAR Working Group was to unify OAR contouring guidance across RTQA groups by compiling a single reference list of OARs in line with AAPM TG 263 and ASTRO, together with peer-reviewed, anatomically defined contouring guidance for integration into clinical trial protocols independent of the radiation therapy delivery technique. MATERIALS AND METHODS: The GHG OAR Working Group comprised of 22 multi-professional members from 6 international RTQA Groups and affiliated organizations conducted the work in 3 stages: (1) Clinical trial documentation review and identification of structures of interest (2) Review of existing contouring guidance and survey of proposed OAR contouring guidance (3) Review of survey feedback with recommendations for contouring guidance with standardized OAR nomenclature. RESULTS: 157 clinical trials were examined; 222 OAR structures were identified. Duplicates, non-anatomical, non-specific, structures with more specific alternative nomenclature, and structures identified by one RTQA group were excluded leaving 58 structures of interest. 6 OAR descriptions were accepted with no amendments, 41 required minor amendments, 6 major amendments, 20 developed as a result of feedback, and 5 structures excluded in response to feedback. The final GHG consensus guidance includes 73 OARs with peer-reviewed descriptions (Appendix A). CONCLUSION: We provide OAR descriptions with standardized nomenclature for use in clinical trials. A more uniform dataset supports the delivery of clinically relevant and valid conclusions from clinical trials.


Subject(s)
Organs at Risk , Quality Assurance, Health Care , Radiotherapy Planning, Computer-Assisted , Clinical Trials as Topic , Consensus , Multicenter Studies as Topic
9.
Radiother Oncol ; 125(3): 398-404, 2017 12.
Article in English | MEDLINE | ID: mdl-29100698

ABSTRACT

PURPOSE: Quality assurance (QA) for clinical trials is important. Lack of compliance can affect trial outcome. Clinical trial QA groups have different methods of dose distribution verification and analysis, all with the ultimate aim of ensuring trial compliance. The aim of this study was to gain a better understanding of different processes to inform future dosimetry audit reciprocity. MATERIALS: Six clinical trial QA groups participated. Intensity modulated treatment plans were generated for three different cases. A range of 17 virtual 'measurements' were generated by introducing a variety of simulated perturbations (such as MLC position deviations, dose differences, gantry rotation errors, Gaussian noise) to three different treatment plan cases. Participants were blinded to the 'measured' data details. Each group analysed the datasets using their own gamma index (γ) technique and using standardised parameters for passing criteria, lower dose threshold, γ normalisation and global γ. RESULTS: For the same virtual 'measured' datasets, different results were observed using local techniques. For the standardised γ, differences in the percentage of points passing with γ < 1 were also found, however these differences were less pronounced than for each clinical trial QA group's analysis. These variations may be due to different software implementations of γ. CONCLUSIONS: This virtual dosimetry audit has been an informative step in understanding differences in the verification of measured dose distributions between different clinical trial QA groups. This work lays the foundations for audit reciprocity between groups, particularly with more clinical trials being open to international recruitment.


Subject(s)
Clinical Trials as Topic/standards , Gamma Rays , Medical Audit , Quality Assurance, Health Care , Humans , Quality Assurance, Health Care/methods , Radiotherapy Dosage
10.
Radiother Oncol ; 123(3): 424-430, 2017 06.
Article in English | MEDLINE | ID: mdl-28478912

ABSTRACT

BACKGROUND AND PURPOSE: The phase III EORTC 1219-DAHANCA 29 intergroup trial evaluates the influence of nimorazole in patients with locally advanced head and neck cancer when treated with accelerated radiotherapy (RT) in combination with chemotherapy. This article describes the results of the RT Benchmark Case (BC) performed before patient inclusion. MATERIALS AND METHODS: The participating centers were asked to perform a 2-step BC, consisting of (1) a delineation and (2) a planning exercise according to the protocol guidelines. Submissions were prospectively centrally reviewed and feedback was given to the submitting centers. Sørensen-Dice similarity index (DSI) and the 95th percentile Hausdorff distance (HD) were retrospectively used to evaluate the agreement between the centers and the expert contours. RESULTS: Fifty-four submissions (34 delineation and 20 planning exercises) from 19 centers were reviewed. Nine (47%) centers needed to perform the delineation step twice and three (16%) centers 3 times before receiving an approval. An increase in DSI-value and a decrease in HD, in particular for the prophylactic Clinical Target Volume (pCTV), could be found for the resubmitted cases. No unacceptable variations could be found for the planning exercise. CONCLUSIONS: These BC-results highlight the need for effective and prospective RTQA in clinical trials. Even with clearly defined protocol guidelines, delineation and not planning remain the main reason for unacceptable protocol variations. The introduction of more objective quantitative analysis methods, such as the HD and DSI, in future trials might strengthen the evaluation by experts.


Subject(s)
Benchmarking , Carcinoma, Squamous Cell/radiotherapy , Head and Neck Neoplasms/radiotherapy , Quality Assurance, Health Care , Carcinoma, Squamous Cell/virology , Head and Neck Neoplasms/virology , Humans , Nimorazole/therapeutic use , Organs at Risk , Prospective Studies , Radiotherapy Planning, Computer-Assisted , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck
11.
Z Med Phys ; 25(3): 210-20, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25779877

ABSTRACT

The goal of modern radiotherapy is to deliver a lethal amount of dose to tissue volumes that contain a significant amount of tumour cells while sparing surrounding unaffected or healthy tissue. Online image guided radiotherapy with stereotactic ultrasound, fiducial-based planar X-ray imaging or helical/conebeam CT has dramatically improved the precision of radiotherapy, with moving targets still posing some methodical problems regarding positioning. Therefore, requirements for precise target delineation and identification of functional body structures to be spared by high doses become more evident. The identification of areas of relatively radioresistant cells or areas of high tumor cell density is currently under development. This review outlines the state of the art of MRI integration into treatment planning and its importance in follow up and the quantification of biological effects. Finally the current state of the art of online imaging for patient positioning will be outlined and indications will be given what the potential of integrated radiotherapy/online MRI systems is.


Subject(s)
Magnetic Resonance Imaging/methods , Neoplasms/pathology , Neoplasms/radiotherapy , Organ Sparing Treatments/methods , Radiotherapy, Image-Guided/methods , Workflow , Humans , Prognosis
12.
Radiother Oncol ; 112(3): 376-80, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25281581

ABSTRACT

BACKGROUND AND PURPOSE: The Facility Questionnaire (FQ) of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group (EORTC-ROG) evaluates the human, technical and organizational resources at each EORTC member institution. The purpose of this study is to use the FQ database to assess the improvement of radiation therapy (RT) structures and resources within the EORTC compared to the previous surveys performed by our group. MATERIAL AND METHODS: We report the content of the current FQ database, completed online by 156 EORTC candidate member institutions from 22 countries between February 2011 and February 2013. Results are compared to FQ-published data from 1992 and 2007. RESULTS: The average number of patients per year per EORTC institution is 2381 (range 350-12,000) an 18.2% increase compared to the 2007 figures. From 2007 to 2013 the average number of radiation oncologists, physicists and radiation technologists per EORTC institution has increased by 27% (from 8.5 to 10.8), 41% (from 5.2 to 7.4) and 38% (from 26.1 to 36.1) respectively. Consequently the number of patients per year per radiation oncologist has decreased from 258 to 243, for physicists from 426 to 354 and for radiation technologists from 107 to 86. One hundred and forty-six (94%) and 101 (65%) institutions can now deliver IMRT and SBRT, compared to 77 (79%) and 53 (54%) in 2007. CONCLUSIONS: The standards set by the EORTC-ROG are met by a continually improving number of institutions, helping to safeguard use of advanced technologies in EORTC-ROG clinical trials.


Subject(s)
Academic Medical Centers/standards , Clinical Trials as Topic/statistics & numerical data , Neoplasms/radiotherapy , Quality Assurance, Health Care/standards , Radiation Oncology/standards , Radiotherapy Planning, Computer-Assisted/standards , Academic Medical Centers/statistics & numerical data , Databases, Factual/statistics & numerical data , Europe , Humans , Quality Assurance, Health Care/methods , Quality Assurance, Health Care/statistics & numerical data , Radiation Oncology/methods , Radiotherapy Planning, Computer-Assisted/methods , Radiotherapy Planning, Computer-Assisted/statistics & numerical data , Surveys and Questionnaires , Workload/statistics & numerical data
13.
Radiother Oncol ; 110(2): 272-7, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24332020

ABSTRACT

PURPOSE: To prospectively evaluate long-term late rectal bleeding (lrb) and faecal incontinence (linc) after high-dose radiotherapy (RT) for prostate cancer in the AIROPROS 0102 population, and to assess clinical/dosimetric risk factors. MATERIALS AND METHODS: Questionnaires of 515 patients with G0 baseline incontinence and bleeding scores (follow-up ≥6 years) were analysed. Correlations between lrb/linc and many clinical and dosimetric parameters were investigated by univariate and multivariate logistic analyses. The correlation between lrb/linc and symptoms during the first 3 years after RT was also investigated. RESULTS: Of 515 patients lrb G1, G2 and G3 was found in 32 (6.1%), 2 (0.4%) and 3 (0.6%) patients while linc G1, G2 and G3 was detected in 50 (9.7%), 3 (0.6%) and 3 (0.6%), respectively. The prevalence of G2-G3 lrb events was significantly reduced compared to the first 3-years (1% vs 2.7%, p=0.016) ≥G1 lrb was significantly associated with V75 Gy (OR=1.07). In multivariate analysis, ≥G1 linc was associated with V40 Gy (OR=1.015), use of antihypertensive medication (OR=0.38), abdominal surgery before RT (OR=4.7), haemorrhoids (OR=2.6), and G2-G3 acute faecal incontinence (OR=4.4), a nomogram to predict the risk of long-term ≥G1 linc was proposed. Importantly, the prevalence of ≥G1 linc was significantly correlated with the mean incontinence score during the first 3 years after RT (OR=16.3). CONCLUSIONS: Long-term (median: 7 years) rectal symptoms are prevalently mild and strongly correlated with moderate/severe events occurring in the first 3 years after RT. Linc was associated with several risk factors.


Subject(s)
Prostatic Neoplasms/physiopathology , Prostatic Neoplasms/radiotherapy , Radiation Injuries/etiology , Radiation Injuries/physiopathology , Rectum/physiopathology , Rectum/radiation effects , Cohort Studies , Fecal Incontinence/etiology , Fecal Incontinence/physiopathology , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/physiopathology , Humans , Male , Multivariate Analysis , Nomograms , Prospective Studies , Radiotherapy Dosage , Radiotherapy, Conformal/adverse effects
14.
Phys Med ; 29(2): 204-7, 2013 Mar.
Article in English | MEDLINE | ID: mdl-22281096

ABSTRACT

Intensity Modulated Radiation Therapy (IMRT) is a complex treatment modality that requires pre-treatment patient-specific quality control (QC) in order to assess a correct treatment delivery. The aim of this work is to investigate pre-treatment patient-specific per-field QCs performed with an on-board EPID at the gantry angle of 0° and at the treatment ones, and to asses if measurements executed at 0° are able to guarantee a correct treatment. Ten patients with prostate cancer were evaluated. Two "verification" plans were created for each patient in order to calculate the dose at the EPID surface: one with all fields positioned at 0° and one with all fields at the actual treatment angles. EPID's mechanical shifts due to gravity effects were always taken into account and corrected. 0 and no-0 plans were compared using a gamma-index method (3%, 3 mm). The gamma index was found dependent on gantry angles but the difference between 0 and no-0 samples was small (-0.3% mean value) and the criteria of acceptability of the gamma method was always satisfied for every field delivered at angles different from 0. Therefore patient-specific pre-treatment QCs should be done at treatments angles, but, if periodical quality assurance is performed on dynamic MLC for different gantry angles, this requirement was shown not strictly mandatory and pre-treatment IMRTQC can be reasonably executed at 0° angles too.


Subject(s)
Precision Medicine/methods , Radiotherapy Planning, Computer-Assisted/methods , Radiotherapy, Intensity-Modulated/methods , Humans , Quality Control , Radiometry
15.
Int J Clin Oncol ; 18(3): 418-27, 2013 Jun.
Article in English | MEDLINE | ID: mdl-22389140

ABSTRACT

BACKGROUND: Set-up errors represent a source of uncertainty in head and neck (H&N) cancer radiotherapy. The present study evaluated set-up accuracy with the use of cone-beam computed tomography (CBCT) in order to establish the proper clinical target volume (CTV) to planning target volume (PTV) margins to be adopted. METHODS: Local set-up accuracy was analysed for 44 H&N cancer patients since the implementation of CBCT. An on-line correction protocol was adopted, with the first 3 scans used to correct systematic errors with a 3-mm action level. The overall mean displacement (M), the population systematic (Σ) and random (σ) errors and the 3D vector length were calculated. PTV margins were calculated according to the van Herk formula (2.5Σ + 0.7σ). RESULTS: A total of 420 CBCT scans were analysed. A systematic correction was needed in 43% of patients. The value of M was <1 mm in all directions; the values of Σ and σ ranged over 1-1.2 and 1.4-1.9 mm, respectively. Pre-correction PTV margins were 3.48, 4.08 and 4.33 mm along the 3 axes. The PTV margins calculated after online correction were <2.5 mm in all directions. CONCLUSIONS: Kilovoltage CBCT is effective in evaluating set-up accuracy in H&N patients. CTV-PTV margins of 5 mm are safe and are currently adopted at our centre; however, some special situations, such as re-irradiation or the close proximity of organs at risk and high-dose regions, could benefit from daily image registration and lower (i.e., 3 mm) margins.


Subject(s)
Cone-Beam Computed Tomography/methods , Head and Neck Neoplasms/radiotherapy , Radiotherapy Planning, Computer-Assisted , Radiotherapy, Image-Guided , Aged , Aged, 80 and over , Female , Head and Neck Neoplasms/pathology , Humans , Male , Middle Aged , Online Systems , Radiotherapy Dosage
16.
Radiother Oncol ; 103(2): 252-5, 2012 May.
Article in English | MEDLINE | ID: mdl-22521747

ABSTRACT

PURPOSE: To evaluate and discuss the role of specific types of abdominal surgery (SURG) before radical radiation therapy as a risk factor for late rectal toxicity in prostate cancer patients. METHODS: Results concerning questionnaire-based scored late bleeding and faecal incontinence in 718 patients with a complete follow-up of 36 months were analysed, focusing on the impact of specific pre-radiotherapy abdominal/pelvic surgery procedures. Patients were accrued in the prospective study AIROPROS 0102. Different types of surgery (rectum-sigma resection, kidney resection, cholecystectomy or appendectomy) were considered as covariates together with a number of different parameters previously found to be predictive of late toxicity and including clinical as well as dosimetric parameters. Univariate (UVA) and multivariate (MVA) logistic analyses were carried out. RESULTS: In total 69/718 patients were previously submitted to one or more surgical procedures, mostly cholecystectomy (n=21) and appendectomy (n=27). Actuarial incidences of G2-G3 and G3 bleeding were 52 (7.2%) and 24 (3.3%) respectively; 19 (2.6%) chronic incontinence events were registered. Cholecystectomy was found to be highly correlated with late rectal bleeding at UVA: OR=4.3 and p=0.006 for G2-G3 and OR=5.4 and p=0.01 for G3. Considering MVA (including dosimetric and clinical factors), G2-G3 bleeding was significantly correlated to cholecystectomy (OR=6.5, p=0.002), V75 Gy (OR=1.074, p=0.003) and secondarily with appendectomy (OR=2.7, p=0.10), presence of acute radioinduced rectal bleeding (OR=1.70, p=0.21) and androgen deprivation (OR=0.67, p=0.25). Appendectomy (OR=5.9, p=0.004) and cholecystectomy (OR=5.5, p=0.016) were very strong predictors of G3 bleeding with V75 Gy playing a less significant role (OR=1.037, p=0.26). Conversely, no specific surgery was correlated with actuarial or chronic incontinence. CONCLUSIONS: This analysis highlights previous SURG as the best predictor of late rectal bleeding. Among the different types of abdominal surgery, cholecystectomy and appendectomy play the major role, especially for severe late bleeding.


Subject(s)
Abdomen/surgery , Gastrointestinal Hemorrhage/etiology , Prostatic Neoplasms/radiotherapy , Rectum/radiation effects , Appendectomy/adverse effects , Cholecystectomy/adverse effects , Fecal Incontinence/etiology , Humans , Logistic Models , Male , Prospective Studies , Radiotherapy Dosage , Risk Factors
17.
Int J Radiat Oncol Biol Phys ; 83(1): 38-45, 2012 May 01.
Article in English | MEDLINE | ID: mdl-21985939

ABSTRACT

PURPOSE: To model late fecal incontinence after high-dose prostate cancer radiotherapy (RT) in patients accrued in the AIROPROS (prostate working group of the Italian Association of Radiation Oncology) 0102 trial using different endpoint definitions. METHODS AND MATERIALS: The self-reported questionnaires (before RT, 1 month after RT, and every 6 months for ≤3 years after RT) of 586 patients were available. The peak incontinence (P_INC) and two longitudinal definitions (chronic incontinence [C_INC], defined as the persistence of Grade 1 or greater incontinence after any Grade 2-3 event; and mean incontinence score [M_INC], defined as the average score during the 3-year period after RT) were considered. The correlation between the clinical/dosimetric parameters (including rectal dose-volume histograms) and P_INC (Grade 2 or greater), C_INC, and M_INC of ≥1 were investigated using multivariate logistic analyses. Receiver operating characteristic curves and the area under the curve were used to assess the predictive value of the different multivariate models. RESULTS: Of the 586 patients, 36 with a Grade 1 or greater incontinence score before RT were not included in the present analysis. Of the 550 included patients, 197 (35.8%) had at least one control with a Grade 1 or greater incontinence score (M_INC >0). Of these 197 patients, 37 (6.7%), 22 (4.0%), and 17 (3.1%) were scored as having P_INC, M_INC ≥1, and C_INC, respectively. On multivariate analysis, Grade 2 or greater acute incontinence was the only predictor of P_INC (odds ratio [OR], 5.9; p = .0009). Grade 3 acute incontinence was predictive of C_INC (OR, 9.4; p = .02), and percentage of the rectal volume receiving >40 Gy of ≥80% was predictive of a M_INC of ≥1 (OR, 3.8; p = .008) and of C_INC (OR, 3.6; p = .03). Previous bowel disease, previous abdominal/pelvic surgery, and the use of antihypertensive (protective factor) correlated highly with both C_INC and M_INC ≥1. The predictive values of the models for C_INC (area under the curve, 0.83) and M_INC ≥1 (area under the curve, 0.73) were greater than the ones for P_INC (area under the curve, 0.62) and more reliable (p = .0001-.0003 against p = .02). Nomograms for the two longitudinal definitions were derived. CONCLUSIONS: The longitudinal definitions of fecal incontinence (C_INC and M_INC ≥1) were helpful in accounting for both the persistence and the severity of the incontinence. A significant fraction of peak events was consequential to acute incontinence, and a longer duration of symptoms mainly depended on the rectal dose bath (percentage of rectal volume receiving >40 Gy), and pretreatment clinical factors.


Subject(s)
Fecal Incontinence/etiology , Prostatic Neoplasms/radiotherapy , Rectum/radiation effects , Surveys and Questionnaires , Acute Disease , Analysis of Variance , Area Under Curve , Humans , Male , Nomograms , Odds Ratio , Predictive Value of Tests , Prospective Studies , Radiotherapy Dosage , Severity of Illness Index
18.
Int J Radiat Oncol Biol Phys ; 82(5): 1957-66, 2012 Apr 01.
Article in English | MEDLINE | ID: mdl-21640511

ABSTRACT

PURPOSE: Development of user-friendly tools for the prediction of single-patient probability of late rectal toxicity after conformal radiotherapy for prostate cancer. METHODS AND MATERIALS: This multicenter protocol was characterized by the prospective evaluation of rectal toxicity through self-assessed questionnaires (minimum follow-up, 36 months) by 718 adult men in the AIROPROS 0102 trial. Doses were between 70 and 80 Gy. Nomograms were created based on multivariable logistic regression analysis. Three endpoints were considered: G2 to G3 late rectal bleeding (52/718 events), G3 late rectal bleeding (24/718 events), and G2 to G3 late fecal incontinence (LINC, 19/718 events). RESULTS: Inputs for the nomogram for G2 to G3 late rectal bleeding estimation were as follows: presence of abdominal surgery before RT, percentage volume of rectum receiving >75 Gy (V75Gy), and nomogram-based estimation of the probability of G2 to G3 acute gastrointestinal toxicity (continuous variable, which was estimated using a previously published nomogram). G3 late rectal bleeding estimation was based on abdominal surgery before RT, V75Gy, and NOMACU. Prediction of G2 to G3 late fecal incontinence was based on abdominal surgery before RT, presence of hemorrhoids, use of antihypertensive medications (protective factor), and percentage volume of rectum receiving >40 Gy. CONCLUSIONS: We developed and internally validated the first set of nomograms available in the literature for the prediction of radio-induced toxicity in prostate cancer patients. Calculations included dosimetric as well as clinical variables to help radiation oncologists predict late rectal morbidity, thus introducing the possibility of RT plan corrections to better tailor treatment to the patient's characteristics, to avoid unnecessary worsening of quality of life, and to provide support to the patient in selecting the best therapeutic approach.


Subject(s)
Fecal Incontinence/etiology , Gastrointestinal Hemorrhage/etiology , Nomograms , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/radiotherapy , Radiation Injuries/complications , Rectum/radiation effects , Abdomen/surgery , Antihypertensive Agents/adverse effects , Antihypertensive Agents/therapeutic use , Hemorrhoids/complications , Humans , Male , Probability , Prospective Studies
19.
Radiother Oncol ; 100(1): 124-30, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21741721

ABSTRACT

BACKGROUND AND PURPOSE: To fit an NTCP model including clinical risk factors to late rectal toxicities after radiotherapy for prostate cancer. METHODS AND MATERIALS: Data of 669 patients were considered. The probability of late toxicity within 36months (bleeding and incontinence) was fitted with the original and a modified Logit-EUD model, including clinical factors by fitting a subset specific TD(50)s: the ratio of TD(50)s with and without including the clinical variable was the dose-modifying factor (D(mod)). RESULTS: Abdominal surgery (surg) was a risk factor for G2-G3 bleeding, reflecting in a TD(50)=82.7Gy and 88.4Gy for patients with and without surg (D(mod)=0.94; 0.90 for G3 bleeding); acute toxicity was also an important risk factor for G2-G3 bleeding (D(mod)=0.93). Concerning incontinence, surg and previous diseases of the colon were the clinical co-factors. D(mod)(surg) and D(mod)(colon) were 0.50 and 0.42, respectively for chronic incontinence and 0.73 and 0.64, respectively for mean incontinence score ⩾1. Best-fit n values were 0.03-0.05 and 1 for bleeding and incontinence, respectively. The inclusion of clinical factors always improved the predictive value of the models. CONCLUSIONS: The inclusion of predisposing clinical factors improves NTCP estimation; the assessment of other clinical and genetic factors will be useful to reduce parameter uncertainties.


Subject(s)
Prostatic Neoplasms/radiotherapy , Radiation Injuries , Rectum/radiation effects , Fecal Incontinence/etiology , Gastrointestinal Hemorrhage/etiology , Humans , Male , Models, Theoretical , Radiotherapy Dosage , Risk Factors
20.
Radiother Oncol ; 93(2): 197-202, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19828205

ABSTRACT

PURPOSE: Assessing the predictors of late rectal toxicity after high-dose conformal radiotherapy for prostate cancer. METHODS: One thousand one hundred thirty-two patients entered a prospective observational multicentric study; late rectal toxicity was evaluated by a self-reported questionnaire. Results concerning bleeding and faecal incontinence of 718/1132 patients with a complete follow-up at 36 months were analysed. The correlation between a number of clinical-dosimetric parameters and moderate/severe toxicity was investigated by univariate and multivariate logistic analyses. RESULTS: Fifty-two (7.2%) and 57/718 (7.9%) patients were scored as moderate/severe bleeders and faecal incontinents, respectively; 19/57 incontinent patients showed persistent incontinence at 36 months. Bleeding was mainly correlated with V75 Gy while severe bleeding was mainly correlated with the previous abdominal/pelvic surgery; a different rectal dose-volume relationship in the two groups of patients (with/without surgery) was found. Moderate/severe acute toxicity was weakly correlated to late bleeding. The best predictor of faecal incontinence was acute toxicity (OR=4 and 7 for chronic and actuarial incontinence, respectively). CONCLUSION: The application of rectal dose-volume constraints limited the incidence of rectal bleeding. The risk of bleeding may be further reduced by limiting V75 Gy<5% and, in the case of patients previously submitted to abdominal/pelvic surgery, V70 Gy<15-20%. Faecal incontinence seems to be mainly a consequential effect after acute toxicity.


Subject(s)
Prostatic Neoplasms/radiotherapy , Radiotherapy, Conformal/adverse effects , Rectum/radiation effects , Fecal Incontinence/etiology , Gastrointestinal Hemorrhage/etiology , Humans , Logistic Models , Male , Prospective Studies , Radiotherapy Dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...